Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients.

Pharmacogenomics - 1 Jan 2024

Ho Teresa T, Perkins Janelle B, Gonzalez Rebecca, Hicks James Kevin, Martinez Ronald Alvarez, Duranceau Katie, North Brianna, Kim Jongphil, Teer Jamie K, Yao Jiqiang, Yoder Sean J, Nishihori Taiga, Bejanyan Nelli, Pidala Joseph, Elmariah Hany

Abstract excerpt

Aim: Successful treatment with tacrolimus to prevent graft versus host disease (GVHD) and minimize tacrolimus-related toxicities among allogeneic hematopoietic cell transplantation (alloHCT) recipients is contingent upon quickly achieving and maintaining concentrations within a narrow therapeutic range. The primary objective was to investigate associations between CYP3A4, CYP3A5 or ABCB1 genotype and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Graft vs Host Disease

Share to Hematopoietic Stem Cell Transplantation

Share to Immunosuppressive Agents

Share to Tacrolimus

Share to Treatment Outcome

Source

Identifiers

PMID: 38189154
DOI: 10.2217/pgs-2023-0204

Genes

CYP3A5
ABCB1
CYP3A4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients.PMID 38189154Read ↗

Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant PatientsSemantic proximity Read ↗

CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration.Semantic proximity Read ↗

Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3.Semantic proximity Read ↗

Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.Semantic proximity Read ↗

Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.Semantic proximity Read ↗

Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.Semantic proximity Read ↗

A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.Semantic proximity Read ↗

Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients.Semantic proximity Read ↗

The CYP3A5 genotypes of both liver transplant recipients and donors influence the time‐dependent recovery of tacrolimus clearance during the early stage following transplantationSemantic proximity Read ↗

The Impact of CYP3A5 Genotype on Tacrolimus Pharmacokinetics in Children following Heart TransplantSemantic proximity Read ↗

Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.